Sfoglia per Titolo
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)
2005-01-01 Bottazzo, Gf; Bosi, Emanuele; Cull, Ca; Bonifacio, E; Locatelli, M; Zimmet, P; Mackay, Ir; Holman, Rr
iAstrocytes do not restrain T cell proliferation in vitro
2023-01-01 Colombo, E.; De Angelis, A.; Bassani, C.; Ruffini, F.; Ottoboni, L.; Garzetti, L.; Finardi, A.; Martino, G.; Furlan, R.; Farina, C.
Iatrogenic damage to corneal endothelium afer cataract surgery
1991-01-01 Buoso, F; Rama, P
Iatrogenic rectal perforation during operative colonoscopy: closure with endoluminal clips
2009-01-01 Sileri, Pierpaolo; DEL VECCHIO BLANCO, Giovanna; Benavoli, D; Gaspari, Achille
Iatrogenic sigmoid perforation by aortobifemoral left graft limb
2008-01-01 Marrocco Trischitta, Mm; Marone, Em; Kahlberg, ANDREA LUITZ; Tshomba, Yamume; Setacci, F; Chiesa, Roberto
IBD and malignancies: The gender matters
2020-01-01 Annese, Vito
IBD Golimumab in ulcerative colitis: a 'menage a trois' of drugs
2013-01-01 Danese, S
IBD IN 2013 Enriching the therapeutic armamentarium for IBD
2014-01-01 Danese, S; Peyrin-Biroulet, L
IBD Mucosal healing-EXTENDing our knowledge in Crohn's disease
2012-01-01 Danese, S; Peyrin-Biroulet, L
IBD Of mice and men-shedding new light on IL-13 activity in IBD
2011-01-01 Danese, S
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
2018-01-01 Momozawa, Y; Dmitrieva, J; Theatre, E; Deffontaine, V; Rahmouni, S; Charloteaux, B; Crins, F; Docampo, E; Elansary, M; Gori, As; Lecut, C; Mariman, R; Mni, M; Oury, C; Altukhov, I; Alexeev, D; Aulchenko, Y; Amininejad, L; Bouma, G; Hoentjen, F; Lowenberg, M; Oldenburg, B; Pierik, Mj; vander Meulen-de Jong, Ae; van der Woude, Cj; Visschedijk, Mc; Lathrop, M; Hugot, Jp; Weersma, Rk; De Vos, M; Franchimont, D; Vermeire, S; Kubo, M; Louis, E; Georges, M; Abraham, C; Achkar, Jp; Ahmad, T; Ananthakrishnan, An; Andersen, V; Anderson, Ca; Andrews, Jm; Aumais, G; Annese, V; Baidoo, L; Baldassano, Rn; Bampton, Pa; Barclay, M; Barrett, Jc; Bayless, Tm; Bethge, J; Bitton, A; Boucher, G; Brand, S; Brandt, B; Brant, Sr; Buning, C; Chew, A; Cho, Jh; Cleynen, I; Cohain, A; Croft, A; Daly, Mj; D'Amato, M; Danese, S; De Jong, D; Denapiene, G; Denson, La; Devaney, Kl; Dewit, O; D'Inca, R; Dubinsky, M; Duerr, Rh; Edwards, C; Ellinghaus, D; Essers, J; Ferguson, Lr; Festen, Ea; Fleshner, P; Florin, T; Franke, A; Fransen, K; Gearry, R; Gieger, C; Glas, J; Goyette, P; Green, T; Griffiths, Am; Guthery, Sl; Hakonarson, H; Halfvarson, J; Hanigan, K; Haritunians, T; Hart, A; Hawkey, C; Hayward, Nk; Hedl, M; Henderson, P; Hu, Xh; Huang, Hl; Hui, Ky; Imielinski, M; Ippoliti, A; Jonaitis, L; Jostins, L; Karlsen, Th; Kennedy, Na; Khan, Ma; Kiudelis, G; Krishnaprasad, K; Kugathasan, S; Kupcinskas, L; Latiano, A; Laukens, D; Lawrance, Ic; Lee, Jc; Lees, Cw; Leja, M; Van Limbergen, J; Lionetti, P; Liu, Jz; Mahy, G; Mansfield, J; Massey, D; Mathew, Cg; Mcgovern, Dpb; Milgrom, R; Mitrovic, M; Montgomery, Gw; Mowat, C; Newman, W; Ng, A; Ng, Sc; Ng, Sme; Nikolaus, S; Ning, K; Nothen, M; Oikonomou, I; Palmieri, O; Parkes, M; Phillips, A; Ponsioen, Cy; Potocnik, U; Prescott, Nj; Proctor, Dd; Radford-Smith, G; Rahier, Jf; Raychaudhuri, S; Regueiro, M; Rieder, F; Rioux, Jd; Ripke, S; Roberts, R; Russell, Rk; Sanderson, Jd; Sans, M; Satsangi, J; Schadt, Ee; Schreiber, S; Schulte, D; Schumm, Lp; Scott, R; Seielstad, M; Sharma, Y; Silverberg, Ms; Simms, La; Skieceviciene, J; Spain, Sl; Steinhart, Ah; Stempak, Jm; Stronati, L; Sventoraityte, J; Targan, Sr; Taylor, Km; ter Velde, A; Torkvist, L; Tremelling, M; van Sommeren, S; Vasiliauskas, E; Verspaget, Hw; Walters, T; Wang, K; Wang, Mh; Wei, Z; Whiteman, D; Wijmenga, C; Wilson, Dc; Winkelmann, J; Xavier, Rj; Zhang, B; Zhang, Ck; Zhang, H; Zhang, W; Zhao, Hy; Zhao, Zz
IBD To switch or not to switch: that is the biosimilar question
2017-01-01 Danese, S; Peyrin-Biroulet, L
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
2019-01-01 Tam, C. S.; Siddiqi, T.; Allan, J. N.; Kipps, T. J.; Flinn, I. W.; Kuss, B. J.; Opat, S.; Barr, P. M.; Tedeschi, A.; Jacobs, R.; Badoux, X. C.; Ghia, P.; Sukbuntherng, J.; Salem, A. H.; Russell, K.; Eckert, K.; Zhou, C.; Ninomoto, J.; James, D. F.; Wierda, W. G.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
2015-01-01 Burger, Ja; Tedeschi, A; Barr, Pm; Robak, T; Owen, C; Ghia, P; Bairey, O; Hillmen, P; Bartlett, Nl; Li, J; Simpson, D; Grosicki, S; Devereux, S; Mccarthy, H; Coutre, S; Quach, H; Gaidano, G; Maslyak, Z; Stevens, Da; Janssens, A; Offner, F; Mayer, J; O'Dwyer, M; Hellmann, A; Schuh, A; Siddiqi, T; Polliack, A; Tam, Cs; Suri, D; Cheng, M; Clow, F; Styles, L; James, Df; Kipps, Tj; for the RESONATE-2, Investigators
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia
2022-01-01 Forestieri, Gabriela; Terzi di Bergamo, Lodovico; Deodato, Marina; Frustaci, Anna Maria; Moia, Riccardo; Deambrogi, Clara; Rasi, Silvia; Autore, Francesco; Merli, Michele; Mattarucchi, Roberta; Fahrni, Gaby; Scarfo', Lydia; Gussetti, Daniela; Bulian, Pietro; Zanatta, Annagiulia; Spina, Valeria; Bruscaggin, Alessio; Pini, Katia; Piffaretti, Deborah; Pirosa, Maria Cristina; Salehi, Matin; Marques de Almeida, Joyce; Passweg, Jakob; Cavalli, Franco; Zucca, Emanuele; Gerber, Bernhard; Stussi, Georg; Gattei, Valter; Ghia, Paolo; Gregor, Michael; Passamonti, Francesco; Laurenti, Luca; Gaidano, Gianluca; Tedeschi, Alessandra; Rossi, Davide; Condoluci, Adalgisa
Ibrutinib holds promise for patients with 17p deletion CLL
2016-01-01 Ghia, PAOLO PROSPERO
Ibrutinib in CLL: benefit for all?
2024-01-01 Cuneo, A.; Ghia, P.
Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study
2021-01-01 Tempero, M; Oh, Dy; Tabernero, J; Reni, M; Van Cutsem, E; Hendifar, A; Waldschmidt, Dt; Starling, N; Bachet, Jb; Chang, Hm; Maurel, J; Garcia-Carbonero, R; Lonardi, S; Coussens, Lm; Fong, L; Tsao, Lc; Cole, G Jr; James, D; Macarulla, T.
Ibrutinib in the real world patient: Many lights and some shades
2016-01-01 Ghia, P.; Cuneo, A.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
2021-01-01 Wierda, William G; Allan, John N; Siddiqi, Tanya; Kipps, Thomas J; Opat, Stephen; Tedeschi, Alessandra; Badoux, Xavier C; Kuss, Bryone J; Jackson, Sharon; Moreno, Carol; Jacobs, Ryan; Pagel, John M; Flinn, Ian; Pak, Yvonne; Zhou, Cathy; Szafer-Glusman, Edith; Ninomoto, Joi; Dean, James P; James, Danelle F; Ghia, Paolo; Tam, Constantine S
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) | 1-gen-2005 | Bottazzo, Gf; Bosi, Emanuele; Cull, Ca; Bonifacio, E; Locatelli, M; Zimmet, P; Mackay, Ir; Holman, Rr | |
| iAstrocytes do not restrain T cell proliferation in vitro | 1-gen-2023 | Colombo, E.; De Angelis, A.; Bassani, C.; Ruffini, F.; Ottoboni, L.; Garzetti, L.; Finardi, A.; Martino, G.; Furlan, R.; Farina, C. | |
| Iatrogenic damage to corneal endothelium afer cataract surgery | 1-gen-1991 | Buoso, F; Rama, P | |
| Iatrogenic rectal perforation during operative colonoscopy: closure with endoluminal clips | 1-gen-2009 | Sileri, Pierpaolo; DEL VECCHIO BLANCO, Giovanna; Benavoli, D; Gaspari, Achille | |
| Iatrogenic sigmoid perforation by aortobifemoral left graft limb | 1-gen-2008 | Marrocco Trischitta, Mm; Marone, Em; Kahlberg, ANDREA LUITZ; Tshomba, Yamume; Setacci, F; Chiesa, Roberto | |
| IBD and malignancies: The gender matters | 1-gen-2020 | Annese, Vito | |
| IBD Golimumab in ulcerative colitis: a 'menage a trois' of drugs | 1-gen-2013 | Danese, S | |
| IBD IN 2013 Enriching the therapeutic armamentarium for IBD | 1-gen-2014 | Danese, S; Peyrin-Biroulet, L | |
| IBD Mucosal healing-EXTENDing our knowledge in Crohn's disease | 1-gen-2012 | Danese, S; Peyrin-Biroulet, L | |
| IBD Of mice and men-shedding new light on IL-13 activity in IBD | 1-gen-2011 | Danese, S | |
| IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes | 1-gen-2018 | Momozawa, Y; Dmitrieva, J; Theatre, E; Deffontaine, V; Rahmouni, S; Charloteaux, B; Crins, F; Docampo, E; Elansary, M; Gori, As; Lecut, C; Mariman, R; Mni, M; Oury, C; Altukhov, I; Alexeev, D; Aulchenko, Y; Amininejad, L; Bouma, G; Hoentjen, F; Lowenberg, M; Oldenburg, B; Pierik, Mj; vander Meulen-de Jong, Ae; van der Woude, Cj; Visschedijk, Mc; Lathrop, M; Hugot, Jp; Weersma, Rk; De Vos, M; Franchimont, D; Vermeire, S; Kubo, M; Louis, E; Georges, M; Abraham, C; Achkar, Jp; Ahmad, T; Ananthakrishnan, An; Andersen, V; Anderson, Ca; Andrews, Jm; Aumais, G; Annese, V; Baidoo, L; Baldassano, Rn; Bampton, Pa; Barclay, M; Barrett, Jc; Bayless, Tm; Bethge, J; Bitton, A; Boucher, G; Brand, S; Brandt, B; Brant, Sr; Buning, C; Chew, A; Cho, Jh; Cleynen, I; Cohain, A; Croft, A; Daly, Mj; D'Amato, M; Danese, S; De Jong, D; Denapiene, G; Denson, La; Devaney, Kl; Dewit, O; D'Inca, R; Dubinsky, M; Duerr, Rh; Edwards, C; Ellinghaus, D; Essers, J; Ferguson, Lr; Festen, Ea; Fleshner, P; Florin, T; Franke, A; Fransen, K; Gearry, R; Gieger, C; Glas, J; Goyette, P; Green, T; Griffiths, Am; Guthery, Sl; Hakonarson, H; Halfvarson, J; Hanigan, K; Haritunians, T; Hart, A; Hawkey, C; Hayward, Nk; Hedl, M; Henderson, P; Hu, Xh; Huang, Hl; Hui, Ky; Imielinski, M; Ippoliti, A; Jonaitis, L; Jostins, L; Karlsen, Th; Kennedy, Na; Khan, Ma; Kiudelis, G; Krishnaprasad, K; Kugathasan, S; Kupcinskas, L; Latiano, A; Laukens, D; Lawrance, Ic; Lee, Jc; Lees, Cw; Leja, M; Van Limbergen, J; Lionetti, P; Liu, Jz; Mahy, G; Mansfield, J; Massey, D; Mathew, Cg; Mcgovern, Dpb; Milgrom, R; Mitrovic, M; Montgomery, Gw; Mowat, C; Newman, W; Ng, A; Ng, Sc; Ng, Sme; Nikolaus, S; Ning, K; Nothen, M; Oikonomou, I; Palmieri, O; Parkes, M; Phillips, A; Ponsioen, Cy; Potocnik, U; Prescott, Nj; Proctor, Dd; Radford-Smith, G; Rahier, Jf; Raychaudhuri, S; Regueiro, M; Rieder, F; Rioux, Jd; Ripke, S; Roberts, R; Russell, Rk; Sanderson, Jd; Sans, M; Satsangi, J; Schadt, Ee; Schreiber, S; Schulte, D; Schumm, Lp; Scott, R; Seielstad, M; Sharma, Y; Silverberg, Ms; Simms, La; Skieceviciene, J; Spain, Sl; Steinhart, Ah; Stempak, Jm; Stronati, L; Sventoraityte, J; Targan, Sr; Taylor, Km; ter Velde, A; Torkvist, L; Tremelling, M; van Sommeren, S; Vasiliauskas, E; Verspaget, Hw; Walters, T; Wang, K; Wang, Mh; Wei, Z; Whiteman, D; Wijmenga, C; Wilson, Dc; Winkelmann, J; Xavier, Rj; Zhang, B; Zhang, Ck; Zhang, H; Zhang, W; Zhao, Hy; Zhao, Zz | |
| IBD To switch or not to switch: that is the biosimilar question | 1-gen-2017 | Danese, S; Peyrin-Biroulet, L | |
| Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study | 1-gen-2019 | Tam, C. S.; Siddiqi, T.; Allan, J. N.; Kipps, T. J.; Flinn, I. W.; Kuss, B. J.; Opat, S.; Barr, P. M.; Tedeschi, A.; Jacobs, R.; Badoux, X. C.; Ghia, P.; Sukbuntherng, J.; Salem, A. H.; Russell, K.; Eckert, K.; Zhou, C.; Ninomoto, J.; James, D. F.; Wierda, W. G. | |
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | 1-gen-2015 | Burger, Ja; Tedeschi, A; Barr, Pm; Robak, T; Owen, C; Ghia, P; Bairey, O; Hillmen, P; Bartlett, Nl; Li, J; Simpson, D; Grosicki, S; Devereux, S; Mccarthy, H; Coutre, S; Quach, H; Gaidano, G; Maslyak, Z; Stevens, Da; Janssens, A; Offner, F; Mayer, J; O'Dwyer, M; Hellmann, A; Schuh, A; Siddiqi, T; Polliack, A; Tam, Cs; Suri, D; Cheng, M; Clow, F; Styles, L; James, Df; Kipps, Tj; for the RESONATE-2, Investigators | |
| Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia | 1-gen-2022 | Forestieri, Gabriela; Terzi di Bergamo, Lodovico; Deodato, Marina; Frustaci, Anna Maria; Moia, Riccardo; Deambrogi, Clara; Rasi, Silvia; Autore, Francesco; Merli, Michele; Mattarucchi, Roberta; Fahrni, Gaby; Scarfo', Lydia; Gussetti, Daniela; Bulian, Pietro; Zanatta, Annagiulia; Spina, Valeria; Bruscaggin, Alessio; Pini, Katia; Piffaretti, Deborah; Pirosa, Maria Cristina; Salehi, Matin; Marques de Almeida, Joyce; Passweg, Jakob; Cavalli, Franco; Zucca, Emanuele; Gerber, Bernhard; Stussi, Georg; Gattei, Valter; Ghia, Paolo; Gregor, Michael; Passamonti, Francesco; Laurenti, Luca; Gaidano, Gianluca; Tedeschi, Alessandra; Rossi, Davide; Condoluci, Adalgisa | |
| Ibrutinib holds promise for patients with 17p deletion CLL | 1-gen-2016 | Ghia, PAOLO PROSPERO | |
| Ibrutinib in CLL: benefit for all? | 1-gen-2024 | Cuneo, A.; Ghia, P. | |
| Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study | 1-gen-2021 | Tempero, M; Oh, Dy; Tabernero, J; Reni, M; Van Cutsem, E; Hendifar, A; Waldschmidt, Dt; Starling, N; Bachet, Jb; Chang, Hm; Maurel, J; Garcia-Carbonero, R; Lonardi, S; Coussens, Lm; Fong, L; Tsao, Lc; Cole, G Jr; James, D; Macarulla, T. | |
| Ibrutinib in the real world patient: Many lights and some shades | 1-gen-2016 | Ghia, P.; Cuneo, A. | |
| Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study | 1-gen-2021 | Wierda, William G; Allan, John N; Siddiqi, Tanya; Kipps, Thomas J; Opat, Stephen; Tedeschi, Alessandra; Badoux, Xavier C; Kuss, Bryone J; Jackson, Sharon; Moreno, Carol; Jacobs, Ryan; Pagel, John M; Flinn, Ian; Pak, Yvonne; Zhou, Cathy; Szafer-Glusman, Edith; Ninomoto, Joi; Dean, James P; James, Danelle F; Ghia, Paolo; Tam, Constantine S |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile